Does Androgen Deprivation Therapy Reduce Severity of COVID-19 in Prostate Cancer Patients?

All-cause 30-day mortality was not improved in infected patients receiving ADT versus those not receiving ADT.

Early in the pandemic, a variety of reports suggested that androgen deprivation therapy (ADT), a widely used treatment for men with advanced prostate cancer, might decrease the severity of COVID-19 in prostate cancer patients infected with SARS-CoV-2. That hypothesis was based on the fact that the TMPRSS2:ERG gene fusion — which leads to an androgen-regulated fusion oncogene — is the most frequent genomic alteration in prostate cancer, and the TMPRSS2 protein is known to play a major role in the pathogenicity of SARS-CoV-2.

To explore whether ADT can modulate outcomes of COVID-19, investigators performed an exploratory cohort analysis of 1106 prostate cancer patients with SARS-CoV-2 infection (median age, 73; 51% non-Hispanic white). The pri…

Reviewing Author

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Does Androgen Deprivation Therapy Reduce Severity of COVID-19 in Prostate Cancer Patients?

Topics

Reviewing Author